15-year survival and related data after first-line brachytherapy

Stone, Stock, and colleagues at the Icahn School of Medicine at Mount Sinai, New York, have been treating prostate cancer patients with brachytherapy since 1990 and (to whatever extent was possible) maintaining meticulous records throughout that time period. … READ MORE …

Data from two large cohorts of Austalian patients on active surveillance

A new paper in BJU International reports on data from a total of 650 Australian patients managed on active surveillance for low-risk, localized prostate cancer. … READ MORE …

Time to prove a treatment-related prostate cancer survival benefit

For most of the past 20 years it has generally been considered that it took 10 years to show that a new form of therapy was effective and safe in the treatment of localized prostate cancer. We may need to seriously re-assess that time period. … READ MORE …

Patient life expectancy and application of radical prostatectomy in Ontario, Canada

An interesting epidemiological study just published on line in the Journal of Urology suggests that urologic surgeons in Ontario, Canada, are rather good at at estimating which patients diagnosed with prostate cancer have a life expectancy of 10+ years, making them reasonable candidates for radical prostatectomy. … READ MORE …

Visceral metastases are NOT a good thing for prostate cancer patients

In an utterly unsurprising finding reported last weekend at the ASCO meeting in Chicago, Halabi et al. reported, based on a meta-analysis of data from nearly 4,000 patients in clinical trials for late-stage prostate cancer, that having visceral (i.e., soft tissue) prostate cancer metastasis is not a good thing at all. … READ MORE …

Can choline-C11 PET/CT scan data predict survival in men with recurrent prostate cancer?

We know that [11C]choline PET/CT scanning can be used to identify sites of recurrence of prostate cancer in men with a rising PSA after first-line therapy. What we do not yet know with clarity is whether such PET/CT scans have any real prognostic value. … READ MORE …

The FDA’s “take” on pre-chemo approval of abiraterone in mCRPC

A new article in Clinical Cancer Research offers us insights into the US Food and Drug Administration’s thinking about the approval of abiraterone acetate for the treatment of chemotherapy-naive patients with metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …

Follow

Get every new post delivered to your Inbox.

Join 1,153 other followers